Steve Hamburg

By: Steve Hamburg on November 17th, 2026

Print/Save as PDF

DEA Telemedicine Rules Expire Dec 31: What Pain Practices Do Next

Medical Billing / RCM | Telemedicine Software

You've got patients on stable regimens you haven't seen in person since 2023. Their refills run through video visits, and it works. Now the calendar is closing in.

The federal flexibilities that let you prescribe controlled substances by telemedicine without a prior in-person exam end on December 31, 2026. As of this writing, the permanent rule that's supposed to replace them still isn't public.

 

Here's where things stand, what could happen on January 1 and what your pain practice can do now so no patient's care stalls.

 

Where the Rule Stands Right Now

In late 2025, DEA and HHS issued a fourth temporary extension of the pandemic era flexibilities. It lets DEA-registered practitioners prescribe Schedule II through V medications by telemedicine without a prior in-person visit through December 31, 2026.

 

The permanent answer is a special registration for telemedicine. DEA proposed it in January 2025. On August 25, 2026, DEA sent a final version to the White House for review, according to Healthcare IT News. The text hasn't been released.

 

The Alliance for Connected Care notes the Justice Department's regulatory agenda lists November 2026 as the target. Even on that timeline, practices would have only weeks to adapt.

 

Three Ways January 1 Could Go

Nobody outside the government knows which way this breaks. So plan for all three. A final rule could publish in November with new registration steps. DEA could issue a fifth extension, as it has four times before. Or the flexibilities could lapse with nothing in place.

 

The last scenario is the one that hurts. Without a rule or an extension, the Ryan Haight Act's in-person exam requirement snaps back for patients you've only treated virtually.

 

This isn't a small group. DEA's own impact analysis in the fourth extension cited data reviewed by Epic, Johns Hopkins and Stanford. It estimated that about 16% of controlled substance prescriptions across 258 organizations in 2024 were issued without a prior in-person evaluation.

 

What the Proposed Registration Would Ask of You

The final rule may differ from the proposal. DEA received more than 6,400 comments, according to Frier Levitt. But the January 2025 proposal shows the direction. It would create special registrations with added recordkeeping and reporting, and it would require a separate DEA telemedicine registration for each state where your patients are located.

 

For a pain practice that sees patients across state lines, that's real administrative work. It also means your prescribing records need to be clean, complete and easy to pull.

 

Your Fourth Quarter Action List

You can't control what DEA publishes. You can control how ready you are. The steps below protect patients in every scenario. They also leave your practice with better records whatever the final rule says.

  • Identify every telemedicine-only patient. Run a report of patients on controlled substances who haven't had an in-person visit with your practice. That's your risk list.
  • Schedule in-person visits early. Book those patients for an in-person evaluation in November or December. If the rule lapses, they're already covered.
  • Tighten prescribing documentation. Make sure each telemedicine encounter records the modality, the clinical rationale and your PDMP check. Auditors will look here first.
  • Map your patients by state. If the final rule keeps state-level registration, you'll need to know exactly where each patient is located.
  • Watch the Federal Register weekly. Assign one person to track DEA and HHS releases so you hear about the rule the day it lands.

 

Where Your Systems Make the Difference

Every step above depends on data. You need to know who your telemedicine patients are, what was documented at each visit and where each patient lives. If that information sits in scattered notes, spreadsheets and a separate telehealth app, you'll be piecing it together in December.

 

Practices that run prescribing, telehealth and billing in one EHR can pull that risk list in minutes. ADS has supported pain management practices since 1977, and our pain management billing team helps practices keep visit documentation and claims aligned as rules shift.

 

For more on keeping pain claims clean, read our pain management medical billing guidelines. Specialty societies like the American Society of Interventional Pain Physicians are also tracking the rule closely, so watch their member updates. And if prescribing changes force a wave of new in-person visits, a strong revenue cycle management process keeps those visits billed correctly.

 

Don't Wait for the Final Word

Four extensions in a row make it tempting to assume a fifth. That's a gamble with your patients' continuity of care. Build your risk list now, get in-person visits on the books and keep your documentation tight. Whatever DEA decides, you'll be ready on January 1.

 

Want prescribing, telehealth and billing records in one place before January 1? Request a live demonstration and see the Medics Suite in your pain management workflow. Or call 1-800-899-4237 ext. 2264. A real person answers in under 2 minutes.

 

Sources: Federal Register, Fourth Temporary Extension of COVID-19 Telemedicine Flexibilities (December 31, 2025); Federal Register, Special Registrations for Telemedicine proposed rule (January 17, 2025); Healthcare IT News; Alliance for Connected Care; Frier Levitt; American Society of Interventional Pain Physicians.